GSK invests in Australian healthcare innovation 10 February 2012 Global pharmaceutical company, GlaxoSmithKlein (GSK), will invest A$60 million to enhance its manufacturing capability and Research & Development activities in Australia. The investment will significantly expand operations at GSK’s manufacturing site in Boronia, Victoria, and will support continued research collaboration with the Monash Institute of Pharmaceutical Sciences. From its base in Australia, GSK manufactures a range of pharmaceutical products utilising advanced blow-fill-seal (BFS) technology. The Boronia site is the company’s largest BFS processing unit globally and its production of antiseptic, sterile BFS containers is expected to double with this latest investment. With additional support from the Victorian Government, GSK’s investment will also create a pilot-scale industrial facility to develop new powder and sterile liquid pharmaceutical products, enhance skills development, and facilitate technology transfer across Australia’s pharmaceutical industry. GSK Boronia Site Director, Troy Webb, said the company’s expanded investment and industry collaboration in Australia will enrich scientific innovation, develop a leading pharmaceutical talent pool, and enhance Australia’s capability across biotechnology and consumer healthcare products. More information |